CVT-6883 (GS 6201) is an A2B adenosine receptor antagonist originated by CV Therapeutics and developed by Gilead Sciences or the treatment of pulmonary diseases. In vitro studies have suggested that the activation of the A2B adenosine receptor may potentially have Proinflammatory and profibrotic effects that could be significant in the development of lung diseases. In adenosine deaminase (ADA) deficient mice, treatment with GS 6201 resulted in significantly less pulmonary inflammation, fibrosis, and alveolar airway enlargement compared with ADA-deficient mice treated with placebo. A range of doses of GS 6201 was well tolerated in healthy volunteers in a phase I multiple ascending dose trial.

Glycodeoxycholic acid (GDCA), a bile acid, is formed in the liver from chenodeoxycholate and glycine. GDCA was one of twenty-five plasma metabolites, which were significantly different among asthma and healthy controls. Besides, GDCA was elevated in patients with acetaminophen-induced acute liver failure (AALF) and was significantly increased in non-surviving AALF patients compared with survivors. Thus GDCA level could serve as a prognostic biomarker for AALF patients.

1,9-Dideoxyforskolin (DFK) is an inhibitor of glucose transporter, has been synthesized in 8 steps and 37% overall yield. 1,9-Dideoxyforskolin is a biologically inactive forskolin analog and does not stimulate adenylyl cyclase. DFK mimics some activity of forskolin, demonstrating alteration of K+ channel activity, reversal of doxorubicin resistance in multidrug resistant sarcoma cells, protection against TNF-α-mediated cytotoxicity, and desensitization at GABAA receptors. The inhibitory effect of DFK on high K (+)-induced contraction was antagonized by an increase in extracellular Ca2+ concentration. DFK inhibited the increase in cytosolic Ca2+ level and contraction in parallel whereas forskolin inhibited the contraction more strongly than the cytosolic Ca2+ level. These results suggest that DFK, but not forskolin, inhibits vascular smooth muscle contraction by a Ca2+ channel blocker-like action.

RO-20-1724 is a potent inhibitor of Phosphodiesterase 4 (PDE4) originally developed by Roche. It showed some promise as a potential treatment for psoriasis, but it was discontinued when it could not match the efficacy of existing treatments. RO-20-1724 was also investigated as a potential treatment for asthma and septic shock.

(R)-Bambuterol is a selective β2-adrenoceptor agonist. R-Bambuterol Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currenTLy on the market. Laevo-Bambuterol was approved by the China Food and Drug Administration for the treatment of asthma.

Chronic myelogenous leukemia (CML) is a hematological malignancy caused by a chromosomal rearrangement that generates a fusion protein, Bcr-Abl, with deregulated tyrosine kinase activity. GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is an allosteric inhibitor of Bcr-Abl that enters the myristate binding pocket at the base of the C-lobe in the Abl kinase domain. When used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochemical and cellular assays against T315I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model. Findings in streptozotocin treated mice (diabetes model) demonstrated that GNF-5 prevented the loss of beta cells and the increase in blood glucose as well as increased insulin protein levels when compared with control mice. In addition GNF-5 inhibited the development of airway hyperresponsiveness and airway remodeling in mouse model of asthma.

ISO-1 inhibits several Macrophage migration inhibitory factor biological activities. The crystal structure of MIF complexed to (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) reveals that ISO-1 binds to the same position of the active site as p-hydroxyphenylpyruvic acid, a substrate of MIF. ISO-1 demonstrated significant protection from sepsis in vivo. Moreover, ISO-1 treatment led to the significant suppression observed in the inflammatory responses associated with the allergen-induced lung inflammation and fibrosis in murine asthma model. MIF inhibition by ISO-1 may be a potential therapeutic strategy for diabetic nephropathy.

15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2) is a cyclopentanone prostaglandin and the agonist of endogenous PPAR gamma ligand, that is formed via the elimination of two molecules of water of prostaglandin D2. 15d-PGJ2 possesses anti-inflammatory effects. Experiments with animal models revealed, that 15d-PGJ2 may represent a potential therapeutic strategy in rheumatoid arthritis. Besides, 15d-PGJ2, given either systemically or locally in mice can control ongoing asthma pathological abnormalities, including eosinophil and neutrophil infiltration, mucus exacerbation, and lung remodeling triggered by ovalbumin. It was suggested, that potential exists to exploit 15d-PGJ2 as a therapeutic agent in asthma. It is known, the determination of individual prostaglandins, including 15d-PGJ2 in urine samples could improve the understanding of particular prostaglandins species under various physiological and pathological conditions. Recently was suggested the sensitive method for determination of 15d-PGJ2 and its application in human plasma samples of patients with diabetes.

4-(3-((4-(2-Methyl-1H-Imidaz-1-yl)Phenyl)Sulfanyl)Phenyl)Tetrahydro-2H-Pyran-4-Carboxamide, better known as CJ13610, is an orally active inhibitor of 5-lipoxygenase. Originally discovered by deCode Genetics, and later developed by Pfizer, CJ13610 has shown promise in preclinical models for pain. The compound was investigated in phase II clinical trials for asthma and chronic obstructive pulmonary disease; however, these efforts have been discontinued.

Ginkgolide A (GA, BN52020), is a terpene lactone constituent of Ginkgo biloba, the ginkgo tree, is the oldest living tree, with a long history of use in traditional Chinese medicine. Ginkgolide A is an effective antagonist of platelet activating factor, an ubiquitous phospholipid that acts as a mediator of numerous pathophysiological conditions. Ginkgolide A displays anxiolytic, antiinflammatory properties, protects from cerebral ischemia in animal models.